MedTrace Logo

Sugammadex Improves Muscle Function After Standard Neuromuscular Recovery

NCT01101139 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2012-12-17

No results posted yet for this study

Summary

This study is designed to investigate, whether Sugammadex improves muscle function after standard neuromuscular recovery (TOF 0.9) from relaxation with rocuronium.

Conditions

  • Neuromuscular Blockade

Interventions

DRUG

Sugammadex

Sugammadex (single intravenous injection 0.25 mg/kg)

DRUG

Placebo

Placebo: single intravenous injection Saline 0.9%

Sponsors & Collaborators

  • Technical University of Munich

    lead OTHER

Principal Investigators

  • Manfred Blobner, M.D. · Klinik für Anaesthesiologie Klinikum München rechts der Isar

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-04-30
Primary Completion
2011-05-31
Completion
2011-06-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01101139 on ClinicalTrials.gov